anti-Betatrophin (human), pAb (IN108)
|Synonyms||Angiopoietin-like Protein 8; ANGPTL8; Lipasin; Refeeding-induced Fat and Liver Protein; RIFL; Betatrophin|
|Product Type||Polyclonal Antibody|
|Immunogen/Antigen||Recombinant human ANGPTL8 (betatrophin).|
Western Blot: (1:1'000)
Note: Tested on recombinant proteins and/or target-protein transfected cell lines in ELISA, Western Blot and/or FACS.
Recognizes human betatrophin.
|Purity Detail||Protein A affinity purified.|
|Formulation||Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
ANGPTL8 (Angiopoietin-like protein 8; RIFL; Lipasin; Betatrophin) is a newly discovered secreted protein of 198 aa that was proposed to promote β cell proliferation and improve glucose tolerance in mice. ANGPTL8 may also function in inhibition of lipase activity and on serum triglyceride regulation. ANGPTL8 is expressed in the liver and in white and brown adipose tissue of mice. In humans, ANGPTL8 is found to be predominantly expressed in the liver. ANGPTL8 levels are reduced by fasting and are elevated upon insulin resistance and during pregnancy. ANGPTL8, according to preliminary data could bind to the macrophage receptor Marco and also to RTN4R, a neuronal receptor. Recently, a study using ANGPTL8 KO mice showed that ANGPTL8 does not play a role in β cell proliferation nor in glycemic control as previously thought, but regulates plasma triglyceride levels.
- Transplantation of betatrophin-expressing adipose-derived mesenchymal stem cells induces β-cell proliferation in diabetic mice: LL. Sun, et al.; Int. J. Mol. Med. 39, 936 (2017)